急性髓系白血病诱导化疗期间使用艾曲泊帕治疗:一项随机、双盲、2期研究
这项随机双盲2期研究在10个国家纳入148例初治急性髓系白血病患者,按1:1随机接受艾曲泊帕或安慰剂联合蒽环类诱导化疗,主要评估安全性与耐受性。结果显示两组3-4级不良事件、血栓栓塞事件及左心室射血分数变化相似,但艾曲泊帕组严重不良事件和死亡比例高于安慰剂组。作者结论认为数据不支持在急性髓系白血病诱导化疗中联合使用艾曲泊帕。
要点
- 艾曲泊帕组严重不良事件24例(32%),安慰剂组14例(20%)。
- 艾曲泊帕组死亡39例(53%),安慰剂组死亡29例(41%)。
- 作者认为数据不支持在急性髓系白血病诱导化疗中联合艾曲泊帕。
核心结论
- 作者结论认为,该试验数据不支持在急性髓系白血病患者的诱导化疗中联合使用艾曲泊帕。
研究设计与样本
- 随机、双盲、2期研究,从10个国家(澳大利亚、比利时、加拿大、希腊、匈牙利、以色列、韩国、波兰、俄罗斯和美国)的临床中心招募初治急性髓系白血病患者。
- 患者按既往恶性血液病史(有或无)和年龄(18-60岁或>60岁)分层,通过自动化交互式语音应答系统随机化方案按1:1随机分配,研究者和患者对治疗设盲。
- 2013年9月7日至2015年1月30日期间评估149例患者资格,148例随机接受艾曲泊帕(n=74)或安慰剂(n=74)。
- 从第4天开始,患者接受标准诱导化疗(柔红霉素静脉推注第1-3天[18-60岁患者90 mg/m2,>60岁患者60 mg/m2],加阿糖胞苷持续静脉输注第1-7天[100 mg/m2]),同时每日一次口服艾曲泊帕200 mg(东亚人群100 mg)或安慰剂,直至血小板计数≥200×10^9/L、达到缓解或诱导化疗开始后42天。
- 主要目标为通过不良事件、左心室射血分数(LVEF)变化和临床实验室参数评估所有治疗患者的安全性和耐受性;研究已完成,ClinicalTrials.gov注册号NCT01890746。
主要发现
- 两组平均(SD)年龄匹配:艾曲泊帕组56.7岁(12.3) vs 安慰剂组56.6岁(11.6);平均(SD)初始血小板计数:艾曲泊帕组59.5×10^9/L(43.3) vs 安慰剂组63.7×10^9/L(48.0);不良风险核型:两组均为16/74例(22%)。
- 最常见3-4级不良事件(任一组≥10%)为发热性中性粒细胞减少(艾曲泊帕组31例[42%] vs 安慰剂组28例[39%])、白细胞计数降低(8例[11%] vs 5例[7%])和低磷血症(3例[4%] vs 9例[13%])。
- 严重不良事件发生于艾曲泊帕组24例(32%) vs 安慰剂组14例(20%);死亡艾曲泊帕组39例(53%) vs 安慰剂组29例(41%)。
- 血栓栓塞事件(艾曲泊帕组5例[7%] vs 安慰剂组4例[6%])和平均(SD)LVEF变化(-2.5%[7.8] vs -4.3%[8.5])相似。
临床怎么用
- 作者结论认为,该试验数据不支持在急性髓系白血病患者的诱导化疗中联合使用艾曲泊帕。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Patients with acute myeloid leukaemia frequently have thrombocytopenia during induction chemotherapy. Eltrombopag, an oral thrombopoietin receptor agonist, stimulates platelet production by a similar mechanism to endogenous thrombopoietin. This study investigated safety and efficacy of eltrombopag versus placebo during anthracycline-based induction treatment of patients with acute myeloid leukaemia. METHODS: In this randomised, double-blind, phase 2 study, treatment-naive patients were recruited from clinical centres across 10 countries (Australia, Belgium, Canada, Greece, Hungary, Israel, South Korea, Poland, Russia, and the USA). Patients with acute myeloid leukaemia of any subtype except M3 and M7 were stratified by antecedent malignant haematological disorder (yes or no) and age (18-60 years or >60 years) and were then randomly assigned (1:1) using an automated interactive voice-response system randomisation schedule. Investigators and patients were blinded to study treatment. Starting on day 4, patients received standard induction chemotherapy (daunorubicin bolus intravenous infusion on days 1-3 [90 mg/m2 for patients aged 18-60 years or 60 mg/m2 for patients aged >60 years], plus cytarabine continuous intravenous infusion on days 1-7 [100 mg/m2]), with eltrombopag 200 mg (100 mg for east Asians) or placebo once daily, until platelet counts were 200 × 109/L or higher, until remission, or after 42 days from the start of induction chemotherapy. The primary objective of the study was safety and tolerability assessed by adverse events, changes in left ventricular ejection fraction (LVEF), and clinical laboratory parameters in all treated patients. This study has been completed and is registered with ClinicalTrials.gov, number NCT01890746. FINDINGS: Between Sept 7, 2013, and Jan 30, 2015, 149 patients were assessed for eligibility and 148 were then randomly assigned to receive eltrombopag (n=74) and placebo (n=74). Groups were matched in mean (SD) age (56·7 years [12·3] in the eltrombopag group vs 56·6 years [11·6] in the placebo group), mean (SD) initial platelet count (59·5 × 109/L [43·3] vs 63·7 × 109/L [48·0]), and poor-risk karyotype (16 [22%] of 74 patients in both groups). The most common grade 3-4 adverse events (≥10% in either group) were febrile neutropenia (31 [42%] vs 28 [39%]), decreased white blood cell count (8 [11%] vs 5 [7%]), and hypophosphataemia (3 [4%] vs 9 [13%]). Serious adverse events occurred in 24 (32%) patients in the eltrombopag group compared with 14 (20%) patients in the placebo group. 39 (53%) patients in the eltrombopag group died versus 29 (41%) patients in the placebo group. Thromboembolic events (5 [7%] vs 4 [6%]) and mean (SD) change in LVEF (-2·5% [7·8] vs -4·3% [8·5]) were similar. INTERPRETATION: Data from this trial do not support combining eltrombopag with induction chemotherapy in patients with acute myeloid leukaemia. FUNDING: Novartis Pharma AG.
引用
- Frey N, Jang JH, Szer J, et al. Eltrombopag treatment during induction chemotherapy for acute myeloid leukaemia: a randomised, double-blind, phase 2 study. Lancet Haematol. 2019. PMID: 30704923. doi:10.1016/S2352-3026(18)30231-X
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。